Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2590043 | 0.85 | SMN1; SMN2 (0.65) | MCOLN3PTGS2POLBLMNAKDM4E | |
| SCHEMBL24478222 | 0.85 | MAPT (0.67) | PTGS1PTGS2POLBLMNACA12 | |
| SCHEMBL30823485 | 0.85 | MAPT (0.67) | PTGS1PTGS2POLBLMNACA12 | |
| SCHEMBL2007287 | 0.84 | POLB (0.70) | PTGS1PTGS2POLBLMNACA12 | |
| SCHEMBL1302040 | 0.83 | MCOLN3 (0.56) | MCOLN3POLBLMNAKDM4EPKM | |
| SCHEMBL11315883 | 0.83 | MCOLN3 (0.60) | MCOLN3POLBLMNAKDM4EPKM | |
| SCHEMBL17476037 | 0.82 | POLB (0.68) | PTGS1PTGS2POLBLMNACA12 | |
| Potassium SCHEMBL17476038 | 0.82 | POLB (0.68) | PTGS1PTGS2POLBLMNACA12 | |
| Potassium SCHEMBL29831526 | 0.82 | POLB (0.68) | PTGS1PTGS2POLBLMNACA12 | |
| SCHEMBL29130942 | 0.82 | POLB (0.61) | MCOLN3POLBLMNAKDM4ECA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111100042-B | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | 苏州诚和医药化学有限公司 | 2022-05-31 | — | — | CN | claimed |
| CN-111100042-A | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | 苏州诚和医药化学有限公司 | 2020-05-05 | — | — | CN | claimed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| CN-119219808-A | Multifunctional ionic polymer, preparation method and application thereof, and ion exchange membrane | 佛山绿动氢能科技有限公司 | 2024-12-31 | — | — | CN | disclosed |
| US-12098119-B2 | Compound used as SIRT6 small-molecule allosteric activator and pharmaceutical composition thereof | NUTSHELL BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-09-24 | — | — | US | disclosed |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | VenatoRx Pharmaceuticals, Inc. | 2024-01-18 | — | — | US | disclosed |
| EP-4251630-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-116710461-A | Sulfonylurea NLRP3 inflammation corpuscle inhibitor | 维纳拓尔斯制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
| CN-111100042-A | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | 苏州诚和医药化学有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-111100042-A | Preparation method of 2-methoxy-5-sulfonamide benzoic acid | 苏州诚和医药化学有限公司 | 2020-05-05 | — | — | CN | disclosed |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2020-04-16 | — | — | US | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3636637-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | Forma Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2020004521-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | 2020-01-02 | — | — | WO | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| WO-2004062661-A1 | 2-‘5-(5-CARBAMIMIDOYL-1H-HETEROARYL)-6-HYDROXYBIPHENYL-3-YL!- CARBOXYLIC ACID DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | REN, CYP11B1, CYP11B2 | MCOLN3 1965/4885PTGS1 1111/4885PTGS2 2263/4885 |
| US-12098119-B2 | Compound used as SIRT6 small-molecule allosteric activator and pharmaceutical composition thereof | SIRT6, SIRT1, SIRT7 | MCOLN3 1801/4885PTGS1 3583/4885PTGS2 3978/4885 |
| US-20200115368-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | MCOLN3 2564/4885PTGS1 301/4885PTGS2 399/4885 |
| US-20240018166-A1 | SULFONYL UREA NLRP3 INFLAMMASOME INHIBITORS | NLRP3, PYCARD, NOD1 | MCOLN3 2827/4885PTGS1 2575/4885PTGS2 3233/4885 |
| US-20220315565-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | MCOLN3 2564/4885PTGS1 301/4885PTGS2 399/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | MCOLN3 3456/4885PTGS1 22/4885PTGS2 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.